/
We are a pioneering gene editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The promise of genomic medicines is supported by the advancing knowledge of the human genome and by harnessing the progress in technologies for cell therapy, gene therapy, and, most recently, gene editing.
The business is unprofitable at the operating level (-394.89% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 25.4% YoY with margins expanding 382.3pp.
ROIC dropped from -64.80% to -76.44%, capital efficiency is deteriorating. Negative free cash flow of -$166M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$39M
▲ +25.4% YoY
Net Income (TTM)
-$109M
▲ +32.5% YoY
Op. Margin
-281.32%
▲ +382.3pp YoY
ROIC
-93.08%
▼ -11.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$141M
▲ +24.3% YoY
Op. Cash Flow (TTM)
-$141M
▲ +21.4% YoY
Net Debt
-$52M
Net Cash Position
Cash & Equiv.
$124M
5Y CAGR: -14.9%
Continue Research